Mergers & Acquisitions
Viewpoints
Filter by:
Federal Reserve Main Street Lending Program: Updates, Timing and Certain Considerations
June 12, 2020 | Advisory | By Joseph Price, Joseph J. Ronca
This article discusses updated documentation and timing for the Federal Reserve Main Street Lending Program and certain considerations for companies considering borrowing under the program.
Read more
Revised Federal Reserve Main Street Lending Program: Terms and Key Considerations
May 18, 2020 | Advisory | By Joseph Price, Joseph J. Ronca
This article discusses the recent revisions to the Federal Reserve’s Main Street Lending Program; borrower considerations regarding eligibility and access to the program; implications of certain covenants and restrictions; and considerations under existing debt documents.
Read more
Does the Coronavirus Change the Material Adverse Event Clause for Mergers & Acquisitions?
May 7, 2020 | Alert
Read about considerations for drafting material adverse change clauses in mergers & acquisitions in light of uncertainties associated with the COVID-19 pandemic.
Read more
Recent Decision in Newmont Mining Reinforces the High Bar Buyers Face when Attempting to Establish a Material Adverse Event
May 4, 2020 | Blog | By Francis Earley, Alec Zadek, Joel Rothman
As parties to merger or acquisition agreements carefully review their agreements to see what, if any, impacts the COVID-19 pandemic may have, the recent decision from the U.S. District Court for the Southern District of New York in Newmont Mining Corp. v. AngloGold Ashanti Ltd. provides meaningful guidance for the interpretation of Material Adverse Effect (“MAE”) provisions in agreements governed by New York law.
Read more
COVID-19 and Poison Pills: The Right Prescription?
April 30, 2020 | Advisory | By Matthew Gardella, Scott M. Stanton, David G. Conway
The coronavirus pandemic continues to have profound effects on the U.S. and global economies. Investor concerns about the impact of COVID-19 and government-imposed restrictions on individuals and businesses have led to unprecedented market volatility. Further material volatility is anticipated. In this environment, publicly traded companies may want to evaluate the adequacy of their corporate defenses to protect their stockholders from such predatory activities.
Read more
The Federal Reserve Main Street Lending Program: Terms and Key Considerations
April 14, 2020 | Advisory | By Joseph Price, Joseph J. Ronca
This article discusses the Federal Reserve’s Main Street Lending Program, including eligibility; impacts on debt service, capital structure, and strategic planning; and potential obstacles under existing debt and other agreements.
Read more
Middle Market Private Equity Fund Strategies for Managing Portfolio Company Defaults
April 10, 2020 | Advisory | By Joseph Price, Matthew B. Gautier
This advisory reviews strategies that sponsors and their portfolio companies can use to manage defaults, including proactive measures to avoid default, amendments and waivers to realign with a company’s revised outlook, sponsor support through equity cures, and lender forbearance.
Read more
M&A in the COVID Era – Part III – A Dealmaker’s Guide to Post–COVID-19 Purchase and Sale Agreements
April 7, 2020 | Advisory | By Matthew T. Simpson
This advisory provides a drafting guide for purchase and sale agreements in the post–COVID-19 era.
Read more
M&A in the COVID Era – Part II – Debt Financing Opportunities for Middle Market PE Funds
April 6, 2020 | Advisory | By Joseph Price, Matthew B. Gautier
This article reviews debt financing opportunities available to investors in a down market and the pros and cons of each type of financing.
Read more
M&A in the COVID Era – Part I – Dealing with Distress: Strategies for Buyers of Distressed Targets in the Post–COVID-19 Era
April 2, 2020 | Advisory | By William Kannel, Matthew T. Simpson
Read about the pros and cons for private company buyers seeking to purchase distressed targets through a formal bankruptcy process in the post–COVID-19 era plus strategies for success.
Read more
Newly Expanded CFIUS Jurisdiction
February 12, 2020 | Alert | By Cory S. Flashner, Steve Ganis, Robert Kidwell, Alyssa C. Scruggs
This alert covers new regulations taking effect on February 13, 2020 that significantly broaden CFIUS’s jurisdiction by granting it significant new review power over foreign investments in US businesses and real estate.
Read more
Pre-Closing Covenants: Operating in the Ordinary Course of Business
January 29, 2020 | Article | By Nicholas V. Perricone
Read about issues to consider when drafting or negotiating transaction agreements with covenants to operate in the “ordinary course” of business between signing and closing.
Read more
Three Things to Learn from Delaware Supreme Court’s Opinion on Board of Director Oversight Duties (Marchand v. Barnhill)
August 6, 2019 | Blog
In June 2019, the Delaware Supreme Court issued a decision reaffirming a risk of director liability where there is no board-level reporting process for essential compliance matters. The facts of the case arise from a 2015 listeria outbreak at Blue Bell manufacturing which resulted in the death of three people. The Delaware case reaffirmed the position that directors may be subject to liability if the director “(1) completely fail[ed] to implement any reporting or information system or controls, or (2) having implemented such a system or controls, consciously fail[ed] to monitor or oversee its operations thus disabling themselves from being informed of risks or problems requiring their attention.”
Read more
Control of Third Party Claims
April 22, 2019 | Alert | By Marc Mantell, Matthew E. Maguire
Indemnification provisions in private company M&A contracts have received a lot of attention in recent years. These provisions are used to allocate risk among participants but there has been a lack of attention paid to another critical provision of these contracts. We highlight the frequency of certain provisions that shift control of these claims and examine the merits of various other approaches.
Read more
Key Takeaways from Akorn v. Fresenius
November 2, 2018 | Video | By Steve Gulotta
In Akorn v. Fresenius, the Delaware Court of Chancery determined that Fresenius validly terminated its agreement to acquire Akorn on the grounds of a material adverse change affecting Akorn’s business. Steve Gulotta discusses the significance of the decision and shares key takeaways.
Read more
Delaware Court Finds “Material Adverse Effect” Allows Buyer to Terminate Merger Agreement
October 3, 2018 | Advisory | By Dean Zioze, Matthew Tikonoff
This article reviews the Delaware Court’s Akorn decision, which allowed a buyer to escape an acquisition transaction because of a material adverse change affecting the seller’s business.
Read more
President Signs Legislation Reforming CFIUS & Export Controls
August 28, 2018 | Alert | By Alexander Hecht, R. Neal Martin
Congress has continued its 57-year tradition of passing an annual defense authorization bill with the John S. McCain National Defense Authorization Act (NDAA) for Fiscal Year 2019 finalized by Congress on August 1 and signed into law by President Trump on August 13. The NDAA makes important reforms and updates to the process by which investments in U.S. businesses by foreign persons are reviewed by the Committee on Foreign Investment in the United States (CFIUS) and updates and codifies Department of Commerce practices related to export controls.
Read more
What to Do Now if You Want to Sell Your Company
August 3, 2018 | Advisory | By Jeremy Glaser
The global M&A market has remained strong from the end of 2017 into 2018, with the total deals announced in the first half of 2018 making it the best period for global M&A yet. With stockholders pressuring larger companies to grow their revenues and the strong liquidity position of many companies, it is a sellers’ market. For companies looking to sell and participate in the record-breaking 2018 global M&A market of $890.7 billion in Q1 and $889 billion closed with $1.3 billion announced in Q2,2 the toughest question is often how to start.
Read more
Not Just Mergers – FTC Highlights Commonly Missed HSR Reportable Transactions
May 16, 2018 | Alert | By Bruce Sokler, Robert Kidwell, Farrah Short
The Premerger Notification Office (the “PNO”) of the Federal Trade Commission (the “FTC”) recently issued a reminder about often overlooked “transactions” that may require notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”).
Read more
“No Shop” Clause Radioactive for Merger’s “Failing Firm” Defense
July 21, 2017 | Alert | By Bruce Sokler, Farrah Short
Last week a Delaware federal district court unsealed its earlier opinion blocking the merger of two radioactive waste disposal companies.
Read more
Explore Other Viewpoints:
- AI: The Washington Report
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Cannabis
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Corporate Governance (ESG)
- Cross-Border Asset Recovery
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- Energy & Sustainability
- Environmental (ESG)
- Environmental Enforcement Defense
- Environmental Law
- Environmental, Social, and Corporate Governance (ESG)
- FDA Regulatory
- False Claims Act
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Impacts of a New US Administration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Probate & Fiduciary Litigation
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Social (ESG)
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology